A 32-year-old woman from Mumbai with a 10-year history of asthma presents with progressive nasal obstruction, anosmia, and recurrent sinusitis despite treatment with intranasal fluticasone. She has a history of aspirin sensitivity and reports worsening symptoms with NSAIDs. Nasal endoscopy reveals bilateral nasal polyps. She undergoes functional endoscopic sinus surgery (FESS) with polypectomy. Which of the following is the most important postoperative management to reduce recurrence?

Explanation

## Postoperative Management of CRSwNP in AERD ### Clinical Context: AERD (Aspirin-Exacerbated Respiratory Disease) **High-Yield:** This patient has the classic triad of AERD: 1. Asthma 2. Chronic rhinosinusitis with nasal polyposis 3. Aspirin/NSAID sensitivity AERD is a severe phenotype of CRSwNP with high recurrence rates (up to 50% within 5 years post-FESS) and requires aggressive postoperative management. ### Postoperative Management Strategy **Key Point:** The cornerstone of postoperative management in CRSwNP, especially AERD, is **topical nasal corticosteroids combined with saline irrigation**, with consideration of **aspirin desensitization** for patients with AERD. ### Mechanism of Benefit | Intervention | Mechanism | Evidence | |--------------|-----------|----------| | **Topical nasal corticosteroids** | Reduces mucosal inflammation, suppresses Type 2 immune response | Gold standard; reduces recurrence by 50% | | **Saline irrigation** | Mechanical clearance of mucus and inflammatory mediators | Adjunctive; improves drug delivery | | **Aspirin desensitization** | Induces tolerance to aspirin, allowing therapeutic use; modulates inflammatory pathways | Reduces polyp recurrence and asthma exacerbations in AERD | | **Leukotriene inhibitors** | Blocks cysteinyl leukotriene receptors; may reduce inflammation | Adjunctive role; not monotherapy | ### Aspirin Desensitization in AERD **Clinical Pearl:** Aspirin desensitization is a specialized procedure performed in controlled settings (usually hospital-based) where patients are exposed to gradually increasing doses of aspirin under medical supervision. Once desensitized, patients require continuous aspirin therapy (650–1300 mg daily) to maintain tolerance. **Benefits of aspirin desensitization:** - Reduces nasal polyp recurrence - Improves asthma control - Decreases sinusitis exacerbations - Allows safe use of NSAIDs ### Postoperative Management Algorithm for AERD ```mermaid flowchart TD A[Post-FESS for AERD]:::outcome --> B[Immediate postoperative care]:::action B --> C[Topical nasal corticosteroids]:::action B --> D[Saline irrigation]:::action A --> E{Aspirin desensitization candidate?}:::decision E -->|Yes| F[Refer for aspirin desensitization]:::action E -->|No| G[Continue topical steroids + saline]:::action F --> H[Desensitization protocol]:::action H --> I[Maintenance aspirin therapy]:::action I --> J[Monitor for recurrence]:::action G --> J J --> K{Recurrence?}:::decision K -->|Yes| L[Consider repeat FESS]:::action K -->|No| M[Continue medical management]:::action ``` ### Why Oral Corticosteroids Alone Are Insufficient **Warning:** Systemic corticosteroids are not recommended as first-line postoperative therapy because: - Risk of systemic side effects with prolonged use - Less effective than topical therapy for local sinonasal disease - Do not address the underlying local inflammatory process They may be used briefly (2–4 weeks) for severe postoperative inflammation, but must be transitioned to topical therapy. ### Adjunctive Therapies **High-Yield:** In refractory AERD with CRSwNP: - **Biologic agents:** Dupilumab (anti-IL-4 receptor) has shown promise in reducing polyp burden and asthma exacerbations - **Leukotriene inhibitors:** Montelukast as adjunctive therapy (not monotherapy) - **Immunotherapy:** Consider in patients with concurrent allergic rhinitis [cite:Fokkens et al. EPOS 2020; Szczeklik & Stevenson 2003 on AERD]